https://www.science20.com/newswire/tibotec_presents_interim_findings_tmc435_investigational_genotype_1_hepatitis_c_treatment_aasld_liver_meeting_2008
CORK, Ireland, November 20 /PRNewswire/ -- - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined...
tibotecpresentsinterimfindingsgenotype